CytoSorbents Corporation (CTSO)

[raptorjockey]

Not sure if this has been picked up yet, Keytruda/chemo in 1L-NSCLC converted to full FDA approval based on OS/PFS in KEYNOTE-189 study, (Merck & Co. Inc.) August 20... Warnings included as follows: Immune-mediated adverse reactions, which may be severe or fatal, can occur with KEYTRUDA, including pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, severe skin reactions, solid organ transplant rejection, and complications of allogeneic hematopoietic stem cell transplantation (HSCT). Based on the severity of the adverse reaction, KEYTRUDA should be withheld or discontinued and corticosteroids administered if appropriate. KEYTRUDA can also cause severe or life-threatening infusion-related reactions. Opportunities abound...